C17.2
C17.2 — Malignant neoplasm of ileum
Billable / specific codeICD-10-CM
C17.2 is a billable, specific ICD-10-CM code for malignant neoplasm of ileum. It is valid for submission on a claim.
Excludes1 — never code together
These conditions cannot occur together. Billing both on the same encounter is a denial.
- malignant neoplasm of ileocecal valve (C18.0)
Risk adjustment
C17.2 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 20 Lung and Other Severe Cancers1.136 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C17.2 is named in 72 Medicare coverage policies — 72 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52370Billing and Coding: Bevacizumab and biosimilars
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
Related codes at this level
Codes that share C17. If C17.2 is not quite right, the correct code is usually one of these.
Questions about C17.2
- Is C17.2 a billable ICD-10-CM code?
- Yes. C17.2 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C17.2 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of digestive organs (C15-C26).
- What cannot be coded together with C17.2?
- C17.2 carries an Excludes1 note, which means the conditions it lists can never be coded together with it on the same encounter.